BPD Singapore 2026 at a glance
BPD Singapore 2026 brought the Biopharmaceutical Bioprocess Development Summit to Singapore on 22–23 September 2026. The programme was built around the intersection of biopharmaceutical process development, CMC strategy, market access and cross-border expansion in Asia-Pacific.
| Dates | 22–23 September 2026 |
|---|---|
| Venue | Sands Expo & Convention Centre / Marina Bay Sands, Singapore |
| Reported scale | 60+ speakers and nearly 700 attendees |
| Core themes | CMC, bioprocessing, regulation, market access, AI, advanced modalities and partnering |
Southeast Asia moved to the centre of the conversation
A defining feature of the 2026 programme was the attention given to Southeast Asian regulation, market access and commercialisation. Sessions covered Singapore, Indonesia, Thailand, Malaysia and wider regional cooperation, while the plenary programme focused on how Chinese and global biopharma companies can build partnerships in Southeast Asia.
This matters because market entry in the region is not a single-country exercise. Regulatory pathways, reimbursement, local partnerships, manufacturing requirements and commercial models differ across markets. BPD Singapore positioned Singapore as a practical meeting point between Chinese biopharma, multinational companies, regional regulators, investors and service providers.
CMC and bioprocessing are becoming business strategy, not only technical execution
The agenda showed how CMC is moving beyond a purely operational role. Topics included biologic technology transfer, downstream purification, aseptic fill-finish, risk-based maintenance, global audit compliance, upstream bioprocessing and manufacturing de-risking. These are technical subjects, but they directly affect speed to market, scale-up risk, cost and the ability to transfer products across regions.
For companies expanding in Asia-Pacific, the implication is clear: process development, manufacturing strategy and regulatory planning increasingly have to be designed together. A technically strong process is not enough if it cannot be transferred, validated and operated reliably in the target market.
AI and advanced modalities were no longer side topics
The second day included dedicated content on AI for pharma as well as small nucleic acids, peptides, mRNA, gene therapy and cell therapy. The programme also covered bispecific antibodies and bioconjugation/XDC-related development. The breadth of these tracks reflects a wider change in biopharma: advanced modalities are moving from specialist programmes into mainstream portfolio and manufacturing discussions.
AI was discussed in the context of molecular design, target discovery and practical deployment in pharmaceutical R&D and CMC. For process and manufacturing teams, the important question is increasingly not whether AI will be used, but where it can improve development speed, process understanding, monitoring and decision-making without creating new validation or compliance risks.
Partnering was part of the product
BPD Singapore was not structured only as a sequence of presentations. The programme included multiple partnering blocks, networking periods and closed-door discussions focused on cross-border expansion. That format is important for an event aimed at business development, technology transfer and regional market entry, because many of the useful outcomes happen outside the conference room.
For future visitors to BPD or similar events, the practical lesson is to treat the programme as a meeting platform: identify target companies in advance, group meetings around technical and market-access priorities, and leave enough time for informal follow-up with speakers, regulators and regional partners.
What to watch after BPD Singapore 2026
The strongest themes point to four areas worth following through 2027: regional regulatory alignment, localisation of biomanufacturing, cross-border technology transfer and AI-enabled development. Singapore is likely to remain a useful hub for these conversations because it combines regional access with a dense life-sciences ecosystem and international connectivity.
For ExpoSignal users tracking biopharma events, BPD Singapore is also a good example of why post-event content matters. The value of a conference does not end when the doors close: agendas, speaker topics and partnering themes can reveal where investment, regulation and technology are moving next.
Sources and verification
This report was prepared from the official BPD Singapore programme and post-event information published by the BPD/BIOCHINA network. The event took place on 22–23 September 2026 at Sands Expo & Convention Centre / Marina Bay Sands in Singapore. The post-event wrap-up reported 60+ speakers and nearly 700 attendees.
Sources checked on 27 September 2026: official BPD Singapore programme, BPD LinkedIn updates and BIOCHINA post-event updates. Figures and programme details may be updated by the organiser.